YAP1 and retinoblastoma: In particular, non-light activated VP was shown to inhibit the transcriptional output of the HIPPO growth regulatory pathway (the name comes from one of its key signaling components the protein kinase Hippo (HPO) - mutations in this gene results in tissue overgrowth or a “hippopotamus” like phenotype) by binding to Yes-associated protein (YAP; encoded by YAP1) and disrupting the YAP1-TEAD/TEF complex inhibiting the growth of hepatocellular carcinoma, retinoblastoma and uveal melanoma11, 13, 14.